Skip to main content


The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis

Article metrics



The chemokine CXCL13 has been discussed as a diagnostic parameter with high specificity for Lyme neuroborreliosis (LNB) and as a marker of disease activity. Neurosyphilis and LNB share similar characteristics. We investigated retrospectively CXCL13 levels in the cerebrospinal fluid (CSF) of patients with neurosyphilis at initial diagnosis and during treatment.


Five patients with neurosyphilis were identified retrospectively using an electronic database in a tertiary care hospital from 2005 to 2012. CXCL13 levels were measured using an ELISA. Five patients with definite LNB and 10 patients with multiple sclerosis (MS) served as controls. Median CXCL13 levels at baseline were 972 pg/mL for neurosyphilis patients, 8,000 pg/mL for LNB patients, and 7.8 pg/mL for MS patients. Patients with LNB and neurosyphilis showed significantly higher CXCL13 levels in their CSF compared to MS patients (p < 0.05, p < 0.001, respectively). CXCL13 levels in the CSF declined during treatment.


CXCL13 levels in the CSF of patients with neurosyphilis can be as high as in patients with LNB, exceeding the proposed threshold of 250 pg/mL for the diagnosis of LNB. Patients with encephalitic/myelitic syndromes appear to have especially high levels of CXCL13. Clinicians should be aware that high levels of CXCL13 are not found exclusively in LNB but also in other infectious diseases of the CNS.


Syphilis is a sexually transmitted spirochetal disease caused by Treponema pallidum subspecies pallidum. The incidence of syphilis has been on the rise in western countries over recent years, and late manifestations of the disease occur with an incidence of approximately 7/100,000 inhabitants in the United States [1]. A more frequent occurrence of patients with neurosyphilis is to be expected in the coming years [2]. The chemokine CXCL13 is produced by antigen-presenting cells and is thought to play a role in attracting B cells and B-helper T cells into the cerebrospinal fluid (CSF) in neuroinfectious diseases [3]. CXCL13 is expressed at high levels in the CSF of patients with Lyme neuroborreliosis (LNB) [47]. The sensitivity and specificity of CXCL13 for the diagnosis of LNB are reported to be above 90% [4, 8]. Other non-infectious inflammatory diseases of the nervous system, like multiple sclerosis (MS), show only slight elevations of CXCL13 levels in the CSF [9]. In addition, CXCL13 levels in the CSF seem to be a surrogate marker for disease activity in LNB as CXCL13 levels correlate with pleocytosis and quickly fall after the initiation of antibiotic treatment [10, 11]. Despite these compelling findings, the specificity of CXCL13 for LNB is a matter of controversy, especially when other subacute diseases of the nervous system are considered. Elevated levels of CXCL13 were also reported for CNS lymphoma, HIV infection, cryptococcosis, and neurosyphilis [9, 1214]. A cut-off at 250 pg/mL was thus proposed by van Burgel et al. [9] to distinguish between LNB and other diseases. However, there is no generally accepted cut-off for diagnosing LNB on the basis of CXCL13 levels in CSF. As neurosyphilis shares some similarities with LNB (e.g., spirochetal origin, subacute course, and similar CSF changes), we aimed to measure CXCL13 levels in the CSF of patients with clinically and serologically definite neurosyphilis before and during antibiotic treatment and compared the results with those of patients with definite LNB and MS.


Using an electronic database search in a tertiary care university hospital (Albert Ludwigs University Freiburg), we retrospectively searched for patients with neurosyphilis from 2005 until 2012. Patients with definite neurosyphilis were diagnosed according to the criteria of the Centers of Disease Control and Prevention and the German Academy of Neurology (Deutsche Gesellschaft für Neurologie). Accordingly, they had to fulfill all of the following criteria: compatible neurological syndrome, CSF pleocytosis [white blood cell (WBC) count >5/µL], dysfunction of the blood–CSF barrier [elevated albumin CSF–serum quotient (QAlb) and total CSF protein], positive Venereal Disease Research Laboratory (VDRL) test in CSF, positive T. pallidum particle agglutination assay (TPPA) in serum and CSF, and fluorescent Treponemal antibody-absorption (FTA-ABS) test in serum [15, 16]. Patients were excluded if they had relevant co-infections that could possibly interfere with the measurement of CXCL13 (e.g., HIV) or were treated with antibiotics before lumbar puncture. Patients with LNB had to fulfill the criteria proposed by Stanek et al. [17] and were matched with neurosyphilis patients for age and sex. MS patients were diagnosed according to the 2010 revised McDonald criteria [18]. They served as a “negative” control group and were not matched for age and sex. CSF samples were collected at the time of diagnosis and during the course of the disease as part of the initial diagnostic work-up via lumbar puncture. Superfluous CSF material was stored for further investigation at −80°C. CSF samples were stored, treated, and analyzed in the same manner for all included patients. CXCL13 levels were measured using an ELISA test system (Quantikine; R&D Systems, Minneapolis, MN, USA) according to the instructions supplied by the manufacturer. Details on the application of the assay for CSF have previously been published [4]. When follow-up CSF samples were available for the neurosyphilis patients, they were also used to measure CXCL13 in order to investigate the role of the chemokine in the course of the disease.

The study was approved by the Ethics Committee of the University Medical Center Freiburg, and written informed consent was obtained from all patients.

For comparisons between multiple groups, the Kruskal–Wallis test with Dunn’s post-test was used. For comparisons between two groups, the Mann–Whitney test was performed. Correlations were investigated with Spearman’s rank correlation coefficient. A p value of <0.05 was regarded as statistically significant. Statistics were performed with Prism 4.0b for Macintosh (GraphPad Software, San Diego, CA, USA).


Using our strict inclusion criteria, five consecutive patients with confirmed neurosyphilis were identified. The clinical, demographic, and CSF routine laboratory characteristics of these patients are shown in Table 1. All neurosyphilis patients had late-stage neurosyphilis. The clinical syndromes were heterogeneous. Subsequent to the first lumbar puncture, patients #1, #3, and #5 were treated with 30 Mio IU penicillin G IV for 14 days while patient #2 was treated with 24 Mio IU penicillin G IV for 14 days. Patient #4 was treated with 24 Mio IU penicillin G IV for 21 days and received additional treatment with corticosteroids to avoid occlusion of the cerebral vessels.

Table 1 Clinical and CSF parameters

The mean WBC count in the CSF at the baseline level was 58/µL (SD 68, range 13–192) in patients with neurosyphilis, 209/µL (SD 138, range 84–427) in patients with LNB, and 5/µL (SD 4.5, range 1–14) in patients with MS. The mean total protein in the CSF at the baseline was 1,154 mg/L (SD 524, range 648–2,150) in patients with neurosyphilis, 1,445 mg/L (SD 711.7, range 977–2,650) in patients with LNB, and 491 mg/L (SD 139, range 345–743) in patients with MS.

The median baseline CXCL13 levels in the CSF samples were 972 pg/mL (IQR 213–6,870, range 134–7,140) for patients with neurosyphilis, 8,000 pg/mL (IQR 4,170–20,747; range 3,247–29,110) for patients with LNB, and 7.8 pg/mL (IQR 7.8–20.6; range 7.8–59.4) for patients with MS. The baseline levels of CXCL13 in patients with neurosyphilis showed a high variance, with the highest values observed in patient #5 with meningoencephalitis (7,140 pg/mL) and in patient #3 with encephalomyelitis (6,600 pg/mL).

There was a non-significant trend toward higher baseline values of CXCL13 in patients with LNB compared to neurosyphilis (Figure 1a). However, the difference in the mean baseline CXCL13 levels was statistically significant for both neurosyphilis and LNB compared to MS (Figure 1a, p < 0.05, p < 0.001, respectively). During the course of treatment, CXCL13 levels rapidly declined in neurosyphilis patients, paralleling the course of WBCs in the CSF (Figure 1b).

Figure 1

a CXCL13 levels in CSF at baseline in patients with neurosyphilis (n = 5), neuroborreliosis (n = 5, LNB), and multiple sclerosis (n = 10, MS). The box includes all values from the first (25%) to the third quartile (75%) while the band inside the box corresponds to the median. The ends of the whiskers represent the range. b CXCL13 levels (left ordinate) and WBC count (right ordinate) in the CSF of neurosyphilis patients during the course of disease. Circles represent the mean, and whiskers represent the standard errors. Correlation with Spearman‘s rank correlation: r = 1.00; p = 0.33.


This is the first controlled study reporting on CXCL13 levels in CSF from patients diagnosed with neurosyphilis but without confounding co-infections at the time of the first diagnosis and during the course of treatment. The presented results stem from a small population, therefore, the conclusions are rather limited. It may be noted that long periods of storage can lead to decreased CXCL13 levels. However, as some of the highest values of CXCL13 were estimated in the oldest samples, this issue seems unlikely. Schiffer et al. [19] report no discernible loss of CXCL13 after repeated cycles of freezing and thawing serum samples. Our main finding is that CXCL13 levels are substantially elevated in CSF from patients with untreated neurosyphilis and can surge as high as previously reported for patients with LNB [13]. Furthermore, the CXCL13 baseline values from 80% of our patients with neurosyphilis exceed the threshold of 250 pg/mL for the diagnosis of LNB proposed by van Burgel et al. [9]. However, there is no generally accepted cut-off for diagnosing LNB on the basis of CXCL13 levels in CSF as reported cut-offs range from <100 to more than 1,000 pg/ml [6, 7]. Whether a general cut-off for diagnosing LNB would be reasonable remains doubtful in the context of our finding that the CSF of patients with neurosyphilis can also show high levels of CXCL13. Other cytokines, such as neopterin, that are elevated in the CSF of LNB patients, but not in patients with other neuroinfectious conditions, are also elevated in the CSF of neurosyphilis patients [5]. Our results are in line with Marra et al. [20] who report similar CXCL13 levels in the CSF of 83 patients with HIV and symptomatic or asymptomatic neurosyphilis. However, HIV may also lead to elevated levels of CXCL13 in CSF, so the results of Marra et al. may not solely be due to neurosyphilis [9].

Levels of CXCL13 in the CSF of patients with neurosyphilis declined during antibiotic therapy, in parallel with the clinical improvement of symptoms and a decrease in the WBC count in the CSF, thus representing another marker of CNS inflammation. CXCL13 levels might be part of the inflammatory response to infection of the CNS with T. pallidum and may serve as a marker of disease activity in neurosyphilis. Marra et al. [20] report declining CXCL13 levels during treatment which is corroborated by our findings. Other reports have shown different CXCL13 levels in the CSF of patients with neurosyphilis, which were found to be remarkably lower than in CSF samples from patients with LNB [9, 14, 21]. This difference could be due to pre-analytical sampling and handling conditions. Different clinical manifestations of neurosyphilis may account for the diverging results. In our study, neurosyphilis patients with encephalitic and/or myelitic syndromes (e.g., spastic gait, seizures, or aphasia) showed the highest CXCL13 levels in their CSF. Both patients with isolated palsies of cranial nerves or cerebral luetic vasculitis showed substantially lower CXCL13 levels. Unfortunately, Rupprecht et al. and van Burgel et al. provide no information on the clinical syndromes. Marra et al. do not provide details on the clinical manifestations of neurosyphilis in their patient population but show that CXCL13 levels are higher in patients with HIV and neurosyphilis compared to patients with HIV and syphilis but without neurological symptoms. A possible association between different neurological manifestations and CXCL13 levels in CSF should be the subject of further prospective investigations in neurosyphilis.

In conclusion, as elevated CXCL13 levels are not pathognomonic for a single condition, interpretation of CSF analysis should only be performed by including measurements of antibodies against both Borrelia burgdorferi and T. pallidum in CSF. Clinicians should be aware that high levels of CXCL13 are not found exclusively in LNB but in various infectious diseases of the CNS.



cerebrospinal fluid


Lyme neuroborreliosis


multiple sclerosis

QAlb :

albumin CSF–serum quotient


venereal disease research laboratory


white blood cells


  1. 1.

    Centers for Disease Control and Prevention. Late and late latent syphilis—reported cases and rates of reported cases by state/area and region in alphabetical order, United States and outlying areas, 2009–2013.

  2. 2.

    Robert Koch Institut. Syphilis in Deutschland 2012. Epidemiol Bull. 2013;44.

  3. 3.

    Krumbholz M, Theil D, Cepok S, Hemmer B, Kivisakk P, Ransohoff RM, et al. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment. Brain. 2006;129(Pt 1):200–11.

  4. 4.

    Senel M, Rupprecht TA, Tumani H, Pfister HW, Ludolph AC, Brettschneider J. The chemokine CXCL13 in acute neuroborreliosis. J Neurol Neurosurg Psychiatry. 2010;81(8):929–33.

  5. 5.

    Hytonen J, Kortela E, Waris M, Puustinen J, Salo J, Oksi J. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation. J Neuroinflammation. 2014;11:103.

  6. 6.

    Cerar T, Ogrinc K, Lotric-Furlan S, Kobal J, Levicnik-Stezinar S, Strle F, et al. Diagnostic value of cytokines and chemokines in Lyme neuroborreliosis. Clin Vaccine Immunol. 2013;20(10):1578–84.

  7. 7.

    Schmidt C, Plate A, Angele B, Pfister HW, Wick M, Koedel U, et al. A prospective study on the role of CXCL13 in Lyme neuroborreliosis. Neurology. 2011;76(12):1051–8.

  8. 8.

    Tjernberg I, Henningsson AJ, Eliasson I, Forsberg P, Ernerudh J. Diagnostic performance of cerebrospinal fluid chemokine CXCL13 and antibodies to the C6-peptide in Lyme neuroborreliosis. J Infect. 2011;62(2):149–58.

  9. 9.

    van Burgel ND, Bakels F, Kroes AC, van Dam AP. Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid. J Clin Microbiol. 2011;49(5):2027–30.

  10. 10.

    Albrecht P, Henke N, Lehmann HC, Macht S, Hefter H, Goebels N, et al. A case of relapsing-remitting neuroborreliosis? Challenges in the differential diagnosis of recurrent myelitis. Case Rep Neurol. 2012;4(1):47–53.

  11. 11.

    Borde JP, Meier S, Fingerle V, Klier C, Hubner J, Kern WV. CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings. BMC Infect Dis. 2012;12:344.

  12. 12.

    Fischer L, Korfel A, Pfeiffer S, Kiewe P, Volk HD, Cakiroglu H, et al. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res. 2009;15(19):5968–73.

  13. 13.

    Rupprecht TA, Lechner C, Tumani H, Fingerle V. CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine. Nervenarzt. 2014;85:459–64.

  14. 14.

    Rupprecht TA, Kirschning CJ, Popp B, Kastenbauer S, Fingerle V, Pfister HW, et al. Borrelia garinii induces CXCL13 production in human monocytes through Toll-like receptor 2. Infect Immun. 2007;75(9):4351–6.

  15. 15.

    Centers for Disease Control and Prevention. Update to CDC’s sexually transmitted diseases treatment guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep. 2012;61(31):590–4.

  16. 16.

    DGN. S1 Leitlinie Neurosyphilis. In: Diener H-C, Weimar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012.

  17. 17.

    Stanek G, Fingerle V, Hunfeld KP, Jaulhac B, Kaiser R, Krause A, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect. 2011;17(1):69–79.

  18. 18.

    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292–302.

  19. 19.

    Schiffer L, Kielstein JT, Haubitz M, Luhrs H, Witte T, Haller H, et al. Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus. 2011;20(5):507–11.

  20. 20.

    Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA. CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis. 2010;37(5):283–7.

  21. 21.

    Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et al. The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis. J Neuroinflammation. 2009;6:42.

Download references

Authors’ contributions

RD conceived of the study and drafted the manuscript. VL, MS, and HT carried out the CXCL13 measurements. TH, SR and OS participated in the design of the study, patient’s care and coordination, and helped to draft the manuscript. All authors read and approved the final manuscript.


The article processing charge was funded by the German Research Foundation (DFG) and the Albert Ludwigs University Freiburg in the funding program Open Access Publishing.

Compliance with ethical guidelines

Competing interests RD, TH, MS, VL, and HT have no competing interests. SR received consulting and lecture fees and grant and research support from Bayer Vital GmbH, Biogen Idec, Merck Serono, Novartis, Sanofi-Aventis, Baxter, RG, and Teva and is a founding executive board member of ravo Diagnostika GmbH. OS has received consulting and lecture fees and grant and research support from Baxter, Bayer Vital GmbH, Biogen Idec, Genzyme, Merck Serono, Novartis, RG, Sanofi-Aventis, and Teva but has no financial or personal relationships with individuals or organizations that could inappropriately influence this publication.

Author information

Correspondence to R Dersch.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dersch, R., Hottenrott, T., Senel, M. et al. The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids Barriers CNS 12, 12 (2015) doi:10.1186/s12987-015-0008-8

Download citation


  • Chemokine
  • CXCL13
  • Neurosyphilis
  • Lyme neuroborreliosis
  • CSF
  • Multiple sclerosis